Published in Blood Weekly, March 17th, 2005
According to published research from Germany, "Due to their plasticity and high proliferation capacity in vitro, human mesenchymal stem cells (MSC) are promising candidates for tissue engineering approaches of mesenchymal tissues like bone, cartilage, or tendon.
"Undifferentiated MSC do not express immunologically relevant cell surface markers. They inhibit the proliferation of allogeneic T-cells in vitro and elicit no immune response after allogeneic or xenogenic transplantation. Thus, MSC ought to be seen as immunoprivileged or immunomodulating...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.